Harvard-wide Program on Antibiotic Resistance
Harvard-wide Program on Antibiotic Resistance
批准号:
10571884
负责人:
Michael S Gilmore
金额:
$229.3万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
未结题
起止时间:
2009-09-01 至 2026-08-31
关键词:
AccelerationAchievementAntibiotic ResistanceAntibioticsAntimicrobial ResistanceAreaAttentionBacteriaBiological SciencesBudgetsCell membraneCellsCessation of lifeCollaborationsCommunicable DiseasesCommunitiesComparative Genomic AnalysisDevelopmentDoctor of PhilosophyESKAPE pathogensEnsureEnterococcusGenomic approachGenus staphylococcusGoalsGram-Negative BacteriaGrowthHospitalsImageImaging technologyIndividualIndustryInfectionInfection ControlInfrastructureInstitutionKnowledgeKnowledge DiscoveryMathematical BiologyMathematicsMicrobeMicrofluidicsMolecularMorbidity - disease rateMothersMulti-Drug ResistanceMutationPathogenesisPharmaceutical PreparationsPhasePublic HealthResearchResearch PersonnelResistanceResourcesRiskRoleScientistSumSystems BiologyTechnologyTherapeuticTimeUnited States National Institutes of HealthVancomycin resistant enterococcusVancomycin-resistant S. aureusWorkantibiotic resistant infectionsantimicrobial resistant infectioncell typecellular imagingcommunity buildingcomparative genomicsdesignexperimental studyfunctional genomicsimprovedinnovationinsightlecturermethicillin resistant Staphylococcus aureusmortalitymultidisciplinarynew technologynext generationnovelnovel strategiesnovel therapeutic interventionnovel therapeuticspreservationprogramsrecruitresponsescreeningsmall moleculestemsynergismtransmission process
中文摘要
点击翻译按钮获取中文摘要
英文摘要
SUMMARY
The goal of the Harvard-wide Program on Antibiotic Resistance is to apply innovative advanced
technologies to developing new strategies for treating leading causes of multidrug resistant
hospital-associated infection caused by staphylococci and enterococci. Although much attention
has appropriately been focused on the recent emergence of pan-resistant gram negative bacteria,
staphylococci and enterococci remain the leading causes of both morbidity and mortality
associated with infection by multidrug resistant ESKAPE pathogens, highlighting the limitation of
current therapeutic approaches. This multi-investigator project brings together experts from fields
ranging from mathematics and systems biology to infectious disease clinicians, and creates an
infrastructure for them to work collaboratively and synergistically, bringing new insights and
capabilities to bear in solving the leading public health crisis of antibiotic resistant infection.
Important discoveries and advances were made in the previous period of support by pressing the
envelope with new technologies, including the most advanced high throughput mutational and
comparative genomic analyses yet conducted on these microbes. In the proposed continuation
period, these technologies will be combined with the latest advances in microfluidics and single
cell time lapse imaging, to reveal new vulnerabilities of these bacteria for targeting by new
compounds. The development and use of innovative screens that de-risk targets as well as unveil
new opportunities, inform the design of new and more efficacious compounds for treating
multidrug resistant staphylococcal and enterococcal infection. Filling critical knowledge gaps
related to the various mechanisms by which microbes survive antibiotic challenge, including
stochastic entry into alternate growth states and actively reducing drug concentration through
efflux, make this program exceptionally comprehensive in its approach. Finally, this project
actively shares its results with the community by establishing and promoting information exchange
and networking with other academic and industry scientists, and by ensuring important antibiotic
discovery knowledge is preserved and transmitted to the next generation of scientists. As a result
of internal and external synergies, the impact of the Harvard-wide Program on Antibiotic
Resistance is much greater than would otherwise be possible through individual research efforts.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Role of Enterococcus Unique Hypothetical EF1909 in Intrinsic β-lactam Resistance
-
批准号:10569041
-
项目类别:
-
资助金额:$21.25万
-
财政年份:2022
-
负责人:Michael S Gilmore
-
依托单位:
The Role of Enterococcus Unique Hypothetical EF1909 in Intrinsic β-lactam Resistance
-
批准号:10464409
-
项目类别:
-
资助金额:$25.3万
-
财政年份:2022
-
负责人:Michael S Gilmore
-
依托单位:
Determinants of Ocular Surface Biogeography
-
批准号:10396467
-
项目类别:
-
资助金额:$41.23万
-
财政年份:2020
-
负责人:Michael S Gilmore
-
依托单位:
Determinants of Ocular Surface Biogeography
-
批准号:10596574
-
项目类别:
-
资助金额:$42.5万
-
财政年份:2020
-
负责人:Michael S Gilmore
-
依托单位:
New understanding of LTA as a determinant of daptomycin susceptibility in VRE E. faecium
-
批准号:9926227
-
项目类别:
-
资助金额:$21.25万
-
财政年份:2019
-
负责人:Michael S Gilmore
-
依托单位:
New understanding of LTA as a determinant of daptomycin susceptibility in VRE E. faecium
-
批准号:9810471
-
项目类别:
-
资助金额:$25.5万
-
财政年份:2019
-
负责人:Michael S Gilmore
-
依托单位:
Administrative Core
-
批准号:9151285
-
项目类别:
-
资助金额:$15.71万
-
财政年份:2016
-
负责人:Michael S Gilmore
-
依托单位:
Subproject 3 New Approaches to Treatment and Prevention of Antibiotic Resistant Infection
-
批准号:9151288
-
项目类别:
-
资助金额:$33.84万
-
财政年份:2016
-
负责人:Michael S Gilmore
-
依托单位:
Molecular Basis for Ocular Surface Tropism in Conjunctivitis
-
批准号:9264533
-
项目类别:
-
资助金额:$41.0万
-
财政年份:2014
-
负责人:Michael S Gilmore
-
依托单位:
Molecular Basis for Ocular Surface Tropism in Conjunctivitis
-
批准号:8670576
-
项目类别:
-
资助金额:$41.0万
-
财政年份:2014
-
负责人:Michael S Gilmore
-
依托单位:
Identification of infection-critical S. aureus traits by TnSeq
-
批准号:8660637
-
项目类别:
-
资助金额:$20.5万
-
财政年份:2013
-
负责人:Michael S Gilmore
-
依托单位:
Enterococcal Pathogenesis:Role of Cytolysin
-
批准号:9322594
-
项目类别:
-
资助金额:$41.0万
-
财政年份:2013
-
负责人:Michael S Gilmore
-
依托单位:
Enterococcal Pathogenesis:Role of Cytolysin
-
批准号:8611481
-
项目类别:
-
资助金额:$38.5万
-
财政年份:2013
-
负责人:Michael S Gilmore
-
依托单位:
Enterococcal Pathogenesis:Role of Cytolysin
-
批准号:9117371
-
项目类别:
-
资助金额:$41.0万
-
财政年份:2013
-
负责人:Michael S Gilmore
-
依托单位:
Identification of infection-critical S. aureus traits by TnSeq
-
批准号:8564610
-
项目类别:
-
资助金额:$23.01万
-
财政年份:2013
-
负责人:Michael S Gilmore
-
依托单位:
Modeling CRISPR to Preserve Antibiotics
-
批准号:8642660
-
项目类别:
-
资助金额:$18.45万
-
财政年份:2013
-
负责人:Michael S Gilmore
-
依托单位:
Modeling CRISPR to Preserve Antibiotics
-
批准号:8503236
-
项目类别:
-
资助金额:$22.01万
-
财政年份:2013
-
负责人:Michael S Gilmore
-
依托单位:
Targeting and Containing the Spread of VRSA
-
批准号:8376874
-
项目类别:
-
资助金额:$29.15万
-
财政年份:2012
-
负责人:Michael S Gilmore
-
依托单位:
Adminstrative Core
-
批准号:8376878
-
项目类别:
-
资助金额:$16.86万
-
财政年份:2012
-
负责人:Michael S Gilmore
-
依托单位:
2011 Microbial Adhesion & Signal Transduction Gordon Research Conference
-
批准号:8118646
-
项目类别:
-
资助金额:$1.2万
-
财政年份:2011
-
负责人:Michael S Gilmore
-
依托单位:
海外基金